拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

交易中 11-11 15:03:45 EST

58.07

+0.94

+1.65%

最高58.19	最低56.94	成交量79.04万
今开57.12	昨收57.13	日振幅2.18%
总市值112.23亿	流通市值111.56亿	总股本1.93亿
成交额4,547万	换手率0.41%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":58.07,"timestamp":1794427419931,"preClose":57.13,"halted":0,"volume":790399,"delay":0,"changeRate":0.01645370208296863,"floatShares":192116189,"shares":193270028,"eps":-0.099074,"marketStatus":"交易中","change":0.94,"latestTime":"11-11 15:03:45 EST","open":57.12,"high":58.185,"low":56.94,"amount":45472555.52486,"amplitude":0.021792,"askPrice":58.08,"askSize":308,"bidPrice":58.04,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.099074,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794430800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":57.13,"preHourTrading":{"tag":"盘前","latestPrice":57.05,"preClose":57.13,"latestTime":"09:29 EST","volume":848,"amount":48476.503424,"timestamp":1794407399999,"change":-0.08,"changeRate":-0.0014,"amplitude":0.030282},"postHourTrading":{"tag":"盘后","latestPrice":57.13,"preClose":57.13,"latestTime":"19:30 EST","volume":46678,"amount":2666704.29,"timestamp":1794357004618,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.397169,"impliedVol":0.3455,"impliedVolPercentile":0.0637},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"1198235225","title":"异动解读｜拜玛林制药盘前上涨5.17%，Wedbush称其收入基础可支持新增长机会","url":"https://stock-news.laohu8.com/highlight/detail?id=1198235225","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198235225?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:03","pubTimestamp":1793783032,"startTime":"0","endTime":"0","summary":"11月4日，拜玛林制药盘前上涨5.17%，报55.557美元，成交额2777.85美元。此次异动的消息面，主要是机构在公司披露三季度业绩后发布最新观点，认为其强化后的收入基础仍可支撑多项新增长机会。最新观点指出，尽管Voxzogo收入偏弱、公司下调指引后股价承压，但指引更多反映订单时点变化而非患者需求走弱；机构预计Voxzogo有望在后续恢复增长，且软骨发育不全相关潜在获批也可提供增量支撑。该机构维持跑赢大市评级，但将目标价从94美元下调至89美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拜玛林制药盘前上涨，机构称收入基础可支撑新增长","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192214517","title":"异动解读｜拜玛林制药盘中下跌5.62%，全年每股收益指引显著低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1192214517","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192214517?lang=zh_cn&edition=full","pubTime":"2026-11-04 00:13","pubTimestamp":1793722393,"startTime":"0","endTime":"0","summary":"11月4日，拜玛林制药盘中下跌5.62%，报54.21美元，成交额7167.09万美元。此次异动的核心催化剂，是公司在披露第三季度业绩后下调全年盈利指引。公司预计全年调整后每股收益为2.80至3.10美元，明显低于市场预期的3.53美元，抵消了单季盈利超预期带来的利好。具体看，公司第三季度调整后每股收益为0.23美元，高于市场预期的0.12美元；营收10.25亿美元，基本与预期持平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拜玛林制药盘中下跌，全年盈利指引远逊预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110433875","title":"异动解读｜拜玛林制药盘后下跌5.12%，全年每股收益指引大幅低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1110433875","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110433875?lang=zh_cn&edition=full","pubTime":"2026-11-03 07:34","pubTimestamp":1793662481,"startTime":"0","endTime":"0","summary":"11月3日，拜玛林制药盘后下跌5.12%，报54.5美元，成交额1153.91万美元。此次异动的核心催化剂是公司在披露第三季度业绩的同时下调全年盈利指引。但更受关注的是，公司预计全年调整后每股收益为2.80至3.10美元，显著低于市场预期的3.53美元。此前公司已提示，收购Alesta相关的在研研发费用及运营支出将对调整后每股收益形成明显拖累，这也削弱了单季盈利超预期带来的正面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拜玛林制药盘后下跌，全年盈利指引远逊预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164263830","title":"拜玛林制药宣布终止Voxzogo在努南综合征儿童患者中的开发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1164263830","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164263830?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:33","pubTimestamp":1789475589,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）近日通过美国证券交易委员会（SEC）文件披露，将于2026年9月15日正式停止Voxzogo在努南综合征儿童患者中的开发计划。这一决定标志着该公司在罕见病治疗领域的战略调整进入新阶段。据悉，该药物此前曾被寄予厚望，但基于最新临床数据及综合评估结果，公司最终做出上述决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4566","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155144420","title":"拜玛林制药宣布任命百时美施贵宝首席研究官Robert Plenge加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1155144420","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155144420?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:06","pubTimestamp":1789391169,"startTime":"0","endTime":"0","summary":"拜玛林制药今日对外宣布，Robert Plenge博士已被正式任命为公司董事会成员。Plenge博士目前担任百时美施贵宝的首席研究官一职，在医药研发领域拥有深厚的学术背景和丰富的行业经验。业界普遍认为，这样一位重量级科研领军人物的加入，无疑将为拜玛林制药在罕见病治疗领域的持续创新注入新的活力。公司方面对Plenge博士的加盟表示热烈欢迎，并期待其在董事会中发挥积极作用，共同推动公司迈向新的发展阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BMRN","IE00B7SZLL34.SGD","BK4139","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157665631","title":"拜玛林制药公布Voxzogo®（Vosoritide）治疗软骨发育不全症III期研究积极结果，成果刊发于《NEJM Evidence》","url":"https://stock-news.laohu8.com/highlight/detail?id=1157665631","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157665631?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:06","pubTimestamp":1788959173,"startTime":"0","endTime":"0","summary":"拜玛林制药今日宣布，其针对Voxzogo在软骨发育不全症治疗中的III期临床研究取得了积极成果，该研究的相关数据已正式发表于权威医学期刊《NEJM Evidence》。此次公布的数据不仅为Voxzogo的适应症拓展提供了坚实的科学依据，也为软骨发育不全症这一罕见病领域带来了新的治疗希望。软骨发育不全症是一种导致身材矮小及骨骼异常的遗传性疾病，长期以来缺乏针对性的药物干预手段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183398041","title":"美股盘前｜美国打击伊朗，美股三大期指小幅走弱；能源股盘前走高，哈里伯顿、雪佛龙涨超2%；游戏驿站盘前涨3%，太平洋煤气电力暴跌17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183398041","media":"老虎资讯综合","labels":["AIColumn"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183398041?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:21","pubTimestamp":1788178865,"startTime":"0","endTime":"0","summary":"热门股异动：受“英特尔将代工SK海力士新一代HBM基础芯片”消息提振，英特尔盘前微涨近0.2%，同时英伟达温和上扬，市场聚焦本周即将召开的AI生态大会；国际油价连涨激活能源板块，雪佛龙、西方石油、马拉松石油盘前普遍上涨约1%；博通在大行上调AI收入预期后小幅续涨，财报临近的情绪升温正在发酵。","market":"hk","thumbnail":"https://static.tigerbbs.com/9fa7c522340c9f1e78e78f0c1543440e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9fa7c522340c9f1e78e78f0c1543440e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"AIColumn","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCG","AON","BMRN","NQmain","ESmain","YMmain","DE","HAL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1163200822","title":"异动解读｜拜玛林制药盘前上涨5.08%，与Ascendis达成全球专利和解获最高20%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1163200822","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163200822?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:10","pubTimestamp":1788174635,"startTime":"0","endTime":"0","summary":"8月31日，拜玛林制药盘前上涨5.08%，报68.82美元/股，成交额30.09万美元。消息面上，拜玛林制药宣布与Ascendis Pharma就罕见病药物Yuviwel达成具有约束力的全球专利和解协议。根据协议，Ascendis将就Yuviwel在美国市场的净销售额向拜玛林支付20%的特许权使用费，在欧盟、巴西及韩国市场的销售额支付18%，支付期限延续至2030年5月。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拜玛林盘前上涨，与Ascendis和解获最高20%分成","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077819","title":"拜玛林制药（BMRN）与Ascendis就罕见病药物达成全球专利和解 获最高20%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077819","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663077819?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:47","pubTimestamp":1788173270,"startTime":"0","endTime":"0","summary":"作为回报，拜玛林制药将向Ascendis授予针对Yuviwel所有现行及潜在适应症以及联合用药方案的专利许可，并撤回在美国国际贸易委员会发起的337调查以及在德国、丹麦、巴西、韩国和美国加州北区法院挂牌的诉讼。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305490","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","BK4566","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BMRN","BK4139","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152003599","title":"拜玛林制药盘前股价攀升5.6%，宣布与Ascendis Pharma达成全球和解","url":"https://stock-news.laohu8.com/highlight/detail?id=1152003599","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152003599?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165495,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）的股价在盘前交易时段上扬5.6%。这一涨幅源于公司宣布已与Ascendis Pharma达成全球和解协议。市场对这一消息反应积极，推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","IE00B7SZLL34.SGD","ASND","MEDI","IE00B19Z3B42.SGD","BMRN","IE0002270589.USD","LU0109394709.USD","IE00B19Z3581.USD","LU0320765992.SGD","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172567405","title":"拜玛林制药将撤销ITC调查；包括多国诉讼在内的所有知识产权索赔已解决","url":"https://stock-news.laohu8.com/highlight/detail?id=1172567405","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172567405?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:02","pubTimestamp":1788156130,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，将撤销美国国际贸易委员会（ITC）的调查。该公司表示，所有知识产权相关主张均已得到解决，其中涵盖了在多个国家进行的诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","ASND","LU0889565916.HKD","MEDI","BMRN","LU0320765992.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113752651","title":"拜玛林制药达成和解协议：获Yuviwel全适应症相关专利许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1113752651","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113752651?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:01","pubTimestamp":1788156073,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，其和解方案中涵盖了一项关键条款——即针对Yuviwel药物所有适应症所涉及的专利，拜玛林将获得相应许可。这项和解内容包括，拜玛林将就其与Yuviwel相关的专利组合授予许可，适用范围覆盖全部适应症领域。根据协议内容，此次许可范围之广，触及Yuviwel所有可能的应用场景。此次公布的协议是整体和解方案的一部分，其核心在于为拜玛林提供清晰的专利使用权限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","IE00B19Z3B42.SGD","BK4566","IE00B19Z3581.USD","BK4139","IE00B7SZLL34.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159264208","title":"拜玛林制药达成授权协议：Ascendis就Yuviwel美国销售支付20%特许权使用费，欧盟、巴西及韩国为18%，持续至2030年5月","url":"https://stock-news.laohu8.com/highlight/detail?id=1159264208","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159264208?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:01","pubTimestamp":1788156072,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布了一项重要授权安排。根据协议条款，Ascendis公司将针对其药物Yuviwel在美国市场的销售额，向拜玛林支付20%的特许权使用费。而在欧盟、巴西及韩国等地区，这一比例则为18%。该支付义务将延续至2030年5月。对Ascendis而言，这一安排意味着其旗舰产品Yuviwel在全球主要市场的商业化进程中，需承担相应的授权成本。随着协议的正式生效，业界将密切关注Yuviwel在各大市场的实际销售表现，以及这一财务安排对两家公司未来业绩的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3581.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4139","BMRN","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191918291","title":"拜玛林制药收购Alesta Therapeutics，斩获低磷酸酯酶症首款潜在口服疗法Ale1，重磅临床项目并入管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1191918291","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191918291?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:31","pubTimestamp":1787056284,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，将收购Alesta Therapeutics公司，以此获得其核心资产Ale1——一款有望成为低磷酸酯酶症首个口服治疗方案的在研药物。此项交易为拜玛林的研发管线增添了一个至关重要的临床项目。此次收购，标志着拜玛林在拓展其产品组合方面迈出了坚实一步。通过整合Alesta Therapeutics的研发实力与拜玛林的商业化经验，双方有望加速Ale1的临床开发进程，早日惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BMRN","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4139","IE0002270589.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180971002","title":"拜玛林制药与N-Lorem达成全球独家授权，共同开发Renu综合征反义寡核苷酸药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1180971002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180971002?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:14","pubTimestamp":1785158066,"startTime":"0","endTime":"0","summary":"拜玛林制药与N-Lorem联合宣布，双方已签署一项全球独家许可协议，旨在推动针对Renu综合征的反义寡核苷酸（ASO）疗法研发。此举标志着两家机构在罕见病治疗领域迈出了关键一步，为患者带来潜在的新希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0002270589.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BMRN","BK4566","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115162702","title":"美国食品药品监督管理局受理拜玛林制药关于Voxzogo® (vosoritide)用于软骨发育不全儿童完全批准的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1115162702","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115162702?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:18","pubTimestamp":1783948727,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理拜玛林制药提交的补充新药申请，该申请旨在为药物Voxzogo® (vosoritide)在治疗儿童软骨发育不全症方面获得完全批准。此举标志着该药物在监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BK4139","BMRN","BK4566","IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127221100","title":"拜玛林制药III期研究显示第52周时年化生长速度增加2.33厘米/年","url":"https://stock-news.laohu8.com/highlight/detail?id=1127221100","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127221100?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308506,"startTime":"0","endTime":"0","summary":"拜玛林制药公司公布的一项III期临床试验数据显示，在治疗第52周时，患者的年化生长速度实现了显著提升，增幅达到2.33厘米/年。这一积极结果凸显了其在研疗法在促进生长方面的潜力，为后续的研发与审批进程提供了关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00B7SZLL34.SGD","BMRN","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151320774","title":"拜玛林制药宣布Voxzogo® (Vosoritide) 在软骨发育不全儿童中取得积极三期关键研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1151320774","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151320774?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308486,"startTime":"0","endTime":"0","summary":"拜玛林制药公布了其药物Voxzogo® (Vosoritide) 针对软骨发育不全儿童患者的三期关键性研究的积极成果。该研究达到了主要终点，显示治疗取得了显著效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BK4139","BK4566","IE00B19Z3581.USD","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101027296","title":"基因疗法后期试验结果喜忧参半，拜玛林制药股价应声下跌1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101027296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101027296?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:47","pubTimestamp":1779112039,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）一项针对遗传性疾病的疗法在后期研究中呈现出复杂的数据结果，市场对此反应审慎，公司股价应声下跌约1%。\n这项关键临床试验的结果未能提供明确一致的成功信号，导致投资者信心受挫。尽管疗法在某些评估指标上显示出积极潜力，但整体数据的混合性引发了对其最终疗效与商业化前景的重新评估。\n股价的即时波动反映了市场对生物科技公司研发管线不确定性的典型定价行为。在高度依赖单一或少数重磅产品驱动的行业里，临床数据的任何模糊性都可能迅速转化为资本市场的压力。此次下跌凸显了在创新疗法开发过程中，从科学验证到市场接纳所面临的严峻挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BMRN","IE0002270589.USD","IE00B19Z3581.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184770893","title":"拜玛林制药ENERGY 3研究：放射学整体印象变化评分未现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1184770893","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184770893?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:11","pubTimestamp":1779109895,"startTime":"0","endTime":"0","summary":"拜玛林制药公司近日公布的ENERGY 3研究结果显示，其评估指标——放射学整体印象变化评分——并未出现具有统计学意义的改善。这一核心数据未能达到研究预设的终点，引发了市场对该疗法潜在疗效的进一步审视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4139","BMRN","BK4566"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0264},{"period":"1month","weight":0.0426},{"period":"3month","weight":-0.1866},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.0847},{"period":"ytd","weight":-0.0387}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.0292},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1005},{"period":"ytd","weight":0.0997}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.62963,"avgChangeRate":0.046047},{"month":2,"riseRate":0.481481,"avgChangeRate":0.016135},{"month":3,"riseRate":0.444444,"avgChangeRate":0.001463},{"month":4,"riseRate":0.481481,"avgChangeRate":-0.01987},{"month":5,"riseRate":0.518519,"avgChangeRate":0.008278},{"month":6,"riseRate":0.592593,"avgChangeRate":0.016302},{"month":7,"riseRate":0.666667,"avgChangeRate":0.039874},{"month":8,"riseRate":0.571429,"avgChangeRate":0.005021},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.015176},{"month":10,"riseRate":0.392857,"avgChangeRate":-0.026338},{"month":11,"riseRate":0.785714,"avgChangeRate":0.058215},{"month":12,"riseRate":0.62963,"avgChangeRate":0.034544}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}